<DOC>
	<DOCNO>NCT00240734</DOCNO>
	<brief_summary>The purpose study compare proportion subject receive either Epoetin alfa ( PROCRITÂ® ) placebo able achieve hemoglobin response , define least 1 gram/deciliter increase baseline Week 17 .</brief_summary>
	<brief_title>Treatment Anemia Diabetic Subjects With CKD</brief_title>
	<detailed_description>This prospective , randomize , double blind , placebo control , multi-center study diabetic subject anemia chronic kidney disease . Subjects randomly assign 1:1 ratio receive either Epoetin alfa ( PROCRIT® ) match placebo sixteen week . Epoetin alfa ( PROCRIT® ) indicate treatment anemia associate chronic renal failure ( pre-dialysis ) , non-myeloid malignancy receive chemotherapy , HIV-infected subject receive zidovudine therapy , anemic subject undergo elective non-cardiac , non-vascular surgery reduce need allogenic blood transfusion high-volume blood loss procedure . This study undertaken ass , well-controlled condition , effect weekly Epoetin alfa ( PROCRIT® ) treatment hemoglobin response diabetic subject anemia chronic kidney disease . The study hypothesis weekly PROCRIT treatment effective achieve hemoglobin response placebo , hemoglobin response define least 1 gram/deciliter increase baseline Week 17 . The subject administer study drug ( PROCRIT® match placebo ) weekly subcutaneous injection health care professional 16 week . The initial dose study drug either PROCRIT® 10,000 U ( 1.0 mL ) match placebo . The maximum dose administer 20,000 U ( 2.0 mL ) .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Subjects clinical diagnosis diabetes mellitus History document proteinuria microalbuminuria A glomerular filtration rate 15 90 mL/minute/1.73m2 Subjects hemoglobin great equal 9.0 /dL less equal 11.0 g/dL . A current diagnosis poorly control high blood pressure ( hypertension ) ( systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 100 mm Hg ) adequate anti hypertensive therapy Subjects severe neuropathy peripheral vascular disease gait instability Subjects schedule receive dialysis course study Subjects transferrin saturation &lt; 20 % ferritin level &lt; 50 ng/dL Subjects active malignancy , define malignancy require current therapy ( surgery , chemotherapy , radiotherapy ) history treatment malignancy last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Chronic renal failure</keyword>
	<keyword>pre-dialysis</keyword>
	<keyword>diabetic</keyword>
</DOC>